Research programme: anti-CD19 antibodies - Bristol-Myers Squibb/Genmab
Latest Information Update: 01 Jul 2015
At a glance
- Originator Bristol-Myers Squibb
- Developer Bristol-Myers Squibb; Genmab
- Class Antibodies
- Mechanism of Action CD19 antigen modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Haematological malignancies